{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:13:59Z","timestamp":1745554439961,"version":"3.40.4"},"reference-count":4,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron"],"published-print":{"date-parts":[[2000]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Although the renoprotective effect of calcium-channel blockers (CCBs) has been examined in several models of hypertensive nephropathy, it remains unclear. It also remains to be clarified whether CCBs prevent the progression to end-stage renal failure in chronic progressive glomerulonephritis (GN). A new rat model of progressive mesangioproliferative GN was used to study the effect of benidipine hydrochloride, a long-acting dihydropyridine CCB, on the clinical features and morphological lesions. &lt;i&gt;Methods:&lt;\/i&gt; This animal model of progressive GN was induced by a single intravenous injection of anti-Thy-1 monoclonal antibody (MoAb 1-22-3) two weeks after unilateral nephrectomy. After 10 weeks of treatment with benidipine (1, 3, and 5\u00a0mg\/kg body weight, p.o.) or hydralazine (5\u00a0mg\/kg body weight, p.o.), systolic blood pressure (SBP), urinary protein excretion, creatinine clearance, glomerulosclerosis index, tubulointerstitial lesion index, glomerular cross-sectional area, and glomerular expression of transforming growth factor-\u03b2 (TGF-\u03b2) and \u03b1-smooth muscle actin (\u03b1-SMA) were measured. &lt;i&gt;Results:&lt;\/i&gt; Untreated rats developed hypertension, massive proteinuria, renal dysfunction, severe glomerular and tubulointerstitial injury, higher glomerular size, and marked glomerular staining for TGF-\u03b2 and \u03b1-SMA, while uninephrectomized control rats did not. Each dose of benidipine and hydralazine equally reduced SBP to uninephrectomized control levels. Three and five mg\/kg\/day of benidipine increased creatinine clearance, ameliorated glomerular and tubulointerstitial injury, and reduced glomerular staining for TGF-\u03b2 and \u03b1-SMA, but 1\u00a0mg\/kg\/day of benidipine and hydralazine failed. Only a dose of 5\u00a0mg\/kg\/day of benidipine reduced glomerular size, although it did not reduce the size to control levels. &lt;i&gt;Conclusion:&lt;\/i&gt; These results indicate that in a rat model of progressive mesangioproliferative GN, benidipine prevents the progression to end-stage renal failure in a dose-dependent manner. This renoprotective action is associated with the suppression of glomerular expression of TGF-\u03b2 and \u03b1-SMA.<\/jats:p>","DOI":"10.1159\/000045787","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T15:42:49Z","timestamp":1050421369000},"page":"315-326","source":"Crossref","is-referenced-by-count":10,"title":["Benidipine, a Long-Acting Calcium-Channel Blocker, Prevents the Progression to End-Stage Renal Failure in a Rat Mesangioproliferative Glomerulonephritis"],"prefix":"10.1159","volume":"86","author":[{"given":"Takamichi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ei","family":"Obata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Onitsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoji","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fujio","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2000,11,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311907"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199710000-00005"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.38.23597"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1998.00964.x"}],"container-title":["Nephron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/45787","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/45787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:47:35Z","timestamp":1745470055000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000045787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":4,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2000,11,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000045787","archive":["Portico"],"relation":{},"ISSN":["1660-8151","2235-3186"],"issn-type":[{"type":"print","value":"1660-8151"},{"type":"electronic","value":"2235-3186"}],"subject":[],"published":{"date-parts":[[2000]]}}}